Management of metastatic renal clear cell cancer: ASCO Guideline rapid recommendation update

Management of metastatic renal clear cell cancer: ASCO Guideline rapid recommendation update - American Society of Clinical Oncology (ASCO)

ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options. See the Appendix for disclaimers and other important information (Appendix 1 and Appendix 2, online only).

Background: In 2022, ASCO published a guideline on the management of metastatic renal clear cell cancer (ccRCC). At that time, no recommendations for or against triplet therapy in this setting were made as that option was not available. Since then, results of the phase III COSMIC 313 trial by Choueiri et al, which compared ipilimumab, nivolumab, and cabozantinib (IpiNivoCabo) against matched placebo with ipilimumab and nivolumab, have been published, providing the signal to update the 2022 guideline.


Read full Guideline